<DOC>
	<DOCNO>NCT00380653</DOCNO>
	<brief_summary>The goal study find high tolerable dose sapacitabine give patient advance leukemias myelodysplastic syndrome .</brief_summary>
	<brief_title>Safety Pharmacology Study Sapacitabine Treat Advanced Leukemias Myelodysplastic Syndromes</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Adult patient advance leukemias myelodysplastic syndrome define section 4.1 ; Eastern Cooperative Oncology Group performance status 02 ; adequate hepatic renal function ; ability swallow capsule ; least 2 week prior chemotherapy , radiation therapy , major surgery investigational anticancer therapy ; recover prior toxicity . Patients know CNS involvement leukemia ; plan undergo allogeneic bone marrow transplant within 4 week ; currently investigational agent ; uncontrolled intercurrent illness ; pregnant lactating woman ; know HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>